RxDoctor Payments Data

Robert Cameron, MD

Interventional Cardiology · Somerset, KYNPI 1366422644

Payments from drug & device makers

$3,496in general payments, 2019–2025

Across 221 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$766
  • Johnson & Johnson$492
  • Sanofi-aventis U.S. LLC$474
  • Amgen$411
  • Merck$254
  • Pfizer$158
  • plus $940 from 21 others

What the payments were for

  • Food & beverage$3,496100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,496 in reported general payments places this provider in the 20th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$168,669
Medicare patients
951
Services billed
3,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban272$238,827
JardianceEmpagliflozin107$106,631
EntrestoSacubitril/Valsartan72$67,792
Repatha SureclickEvolocumab58$47,120
XareltoRivaroxaban45$35,822
FarxigaDapagliflozin Propanediol36$32,558
Repatha PushtronexEvolocumab29$19,960
Praluent PenAlirocumab20$17,827
BrilintaTicagrelor17$11,225
MounjaroTirzepatide11$11,096
Ranolazine ErRanolazine22$7,853
VerquvoVericiguat12$7,713
BenicarOlmesartan Medoxomil11$4,505
Atorvastatin Calcium379$2,445
ClopidogrelClopidogrel Bisulfate343$2,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$158$238,827272 claims
Boehringer IngelheimJardiance$39$106,631107 claims
NovartisEntresto$766$67,79272 claims
AstraZenecaFarxiga, Brilinta$62$43,78353 claims
Johnson & JohnsonXarelto$492$35,82245 claims
MerckVerquvo$254$7,71312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Somerset

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →